Diaceutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:DIUX.F Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
29 Jul 24	BuyUS$192	Jordan Clark	Individual	113	US$1.70
29 Jul 24	BuyUS$188	Susanne Munksted	Individual	111	US$1.70
29 Jul 24	BuyUS$192	Nicholas Roberts	Individual	113	US$1.70
29 Jul 24	BuyUS$192	Julie Browne	Individual	113	US$1.70
22 May 24	BuyUS$65,505	Graham Paterson	Individual	39,934	US$1.64
26 Apr 24	BuyUS$186	Jordan Clark	Individual	145	US$1.28
26 Apr 24	BuyUS$186	Nicholas Roberts	Individual	145	US$1.28
06 Mar 24	BuyUS$42,144	Graham Paterson	Individual	33,564	US$1.26

Insider Trading Volume

Insider Buying: DIUX.F insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of DIUX.F?
Owner Type	Number of Shares	Ownership Percentage
State or Government	877,192	1.04%
Employee Share Scheme	1,645,605	1.95%
General Public	2,839,016	3.37%
VC/PE Firms	10,823,500	12.8%
Individual Insiders	24,394,053	28.9%
Institutions	43,704,769	51.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 90.25% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
20.5%	Peter Keeling	17,252,049	US$18.4m	0%	no data
12.8%	Gresham House Asset Management Limited	10,823,500	US$11.5m	0.04%	0.95%
6.75%	Canaccord Genuity Asset Management Limited	5,687,681	US$6.1m	-1.32%	0.2%
6.44%	Joh. Berenberg, Gossler & Co. KG, Asset Management Arm	5,425,207	US$5.8m	0%	0.18%
4.76%	Universal-Investment-Luxembourg SA	4,009,764	US$4.3m	1.01%	0.06%
4.02%	Danske Capital Denmark	3,387,369	US$3.6m	-7.14%	0.02%
3.69%	Elizabeth Considine	3,112,169	US$3.3m	0%	no data
3.55%	Ryan Keeling	2,990,643	US$3.2m	0%	no data
2.7%	Orange River Management LP	2,273,332	US$2.4m	24.7%	7.17%
2.51%	Octopus Investments Limited	2,118,430	US$2.3m	0%	0.11%
2.5%	Herald Investment Management Ltd.	2,111,000	US$2.2m	-4.52%	0.16%
2.43%	Amati Global Investors Ltd.	2,049,000	US$2.2m	0%	0.28%
2.42%	Canaccord Genuity Wealth (International) Limited	2,039,000	US$2.2m	0%	0.03%
2.06%	Handelsbanken Asset Management	1,739,742	US$1.9m	0.58%	no data
1.95%	Diaceutics Plc, ESOP	1,645,605	US$1.8m	4.74%	no data
1.6%	BNY Mellon Advisors, Inc.	1,345,000	US$1.4m	0%	0.01%
1.37%	Danske Invest Rahastoyhtio Oy	1,152,475	US$1.2m	1.09%	1.81%
1.26%	EdenTree Investment Management Limited	1,060,500	US$1.1m	0%	0.06%
1.09%	Ravenscroft Investment Management	922,678	US$981.7k	-10.7%	0.14%
1.08%	Goldman Sachs Asset Management, L.P.	911,714	US$970.0k	-7.68%	no data
1.07%	River and Mercantile Asset Management LLP	900,000	US$957.6k	0%	0.05%
1.04%	Invest Northern Ireland	877,192	US$933.3k	0%	no data
1.04%	Baillie Gifford & Co.	876,947	US$933.1k	-46.9%	no data
0.83%	Jordan Clark	703,770	US$748.8k	0.07%	no data
0.77%	Bi Asset Management FondsmÆGlerselskab A/S	648,627	US$690.1k	0%	0.01%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/11/05 19:36
End of Day Share Price	2023/08/08 00:00
Earnings	2023/06/30
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Diaceutics PLC is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Hayley Palmer	Canaccord Genuity
Colin Smith	Capital Access Group
Oliver Juggins	Capital Access Group